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Abstract: Fabry disease (FD) is a lysosomal storage disorder caused by mutations of the GLA gene
that lead to a deficiency of the enzymatic activity of α-galactosidase A. Available therapies for FD
include enzyme replacement therapy (ERT) (agalsidase alfa and agalsidase beta) and the chaperone
migalastat. Despite the large body of literature published about ERT over the years, many issues
remain unresolved, such as the optimal dose, the best timing to start therapy, and the clinical
impact of anti-drug antibodies. Migalastat was recently approved for FD patients with amenable
GLA mutations; however, recent studies have raised concerns that “in vitro” amenability may not
always reflect “in vivo” amenability, and some findings on real-life studies have contrasted with
the results of the pivotal clinical trials. Moreover, both FD specific therapies present limitations,
and the attempt to correct the enzymatic deficiency, either by enzyme exogenous administration or
enzyme stabilization with a chaperone, has not shown to be able to fully revert FD pathology and
clinical manifestations. Therefore, several new therapies are under research, including new forms
of ERT, substrate reduction therapy, mRNA therapy, and gene therapy. In this review, we provide
an overview of the state-of-the-art on the currently approved and emerging new therapies for adult
patients with FD.
Keywords: fabry disease; enzyme replacement therapy; agalsidase alfa; agalsidase beta; migalastat;
pegunigalsidase alfa; moss-derived alfa galactosidase A; substrate reduction; mRNA; gene therapy
1. Fabry Disease Overview
Fabry disease (FD) (OMIM 301500) is a rare X-linked lysosomal storage disorder
caused by mutations in the GLA gene, leading to deficiency of the enzymatic activity of
α-galactosidase A. Subsequent accumulation of globotriaosylceramide (GB3) and other
neutral glycosphingolipids occurs in body fluids and lysosomes of cells throughout the
body, including in those that are particularly relevant to disease pathology, such as in the
heart (cardiomyocytes, conduction system cells, vascular endothelial, and smooth muscle
cells and fibroblasts), kidney (podocytes, tubular, glomerular, mesangial, and interstitial
cells), nervous system (neurons in autonomic and posterior root ganglia) and vascular
endothelium and smooth muscle [1,2].
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GLA mutations causing a virtually null enzymatic activity (<5% of the normal mean)
are associated to severe and early onset classical phenotypes, while mutations leading to a
residual enzymatic activity are associated to attenuated and late-onset phenotypes [1–3].
Classical phenotypes are characterized by early development, in childhood or adolescence,
of acroparesthesias, neuropathic pain, hypohydrosis, heat, cold and exercise intolerance,
cornea verticillata, angiokeratomas, gastrointestinal symptoms, and proteinuria. In adult-
hood, patients also suffer from sensorineural deafness and cardiac, renal, and cerebrovascu-
lar manifestations. In contrast, late-onset phenotypes are characterized by the development
of cardiac, renal, and/or cerebrovascular manifestations in adulthood, and the phenotype
may be dominated by the involvement of an organ, such as the heart or the kidneys [2–5].
Cardiac manifestations include left ventricular hypertrophy (LVH), heart failure, angina,
dysrhythmias, cardiac conduction abnormalities, and sudden death. Renal involvement
may lead to end-stage renal failure, and brain involvement is characterized by the devel-
opment of brain white matter lesions (WML) and the occurrence of strokes or transient
ischemic attacks (TIA) [2–5]. In this X-linked disorder, heterozygote females are not merely
carriers, and their clinical spectrum ranges from asymptomatic to full-blown disease as
severe as in affected males [6,7]. Ultimately, FD leads to a reduction of quality of life [8]
and survival, with death being mainly driven by heart disease [9,10].
Available therapies for FD include enzyme replacement therapy (ERT) (agalsidase alfa
and agalsidase beta) and the chaperone migalastat [11]. However, several new therapies are
under research, including new forms of ERT, substrate reduction therapy, mRNA therapy,
and gene therapy [12,13].
2. ERT
2.1. Efficacy and Safety of ERT
ERT with recombinant α-galactosidase A has been approved for clinical use since 2001.
There are two commercially available preparations: agalsidase alfa, produced from human
fibroblasts; and agalsidase beta, produced in Chinese hamster ovary (CHO) cells. Both are
administered intravenously every other week (eow) at doses of 0.2 mg/kg and 1 mg/kg of
body weight, respectively [11].
In males, agalsidase alfa has been demonstrated to decrease plasma GB3 [14–16] and
lyso-GB3 [17] and urinary GB3 [14,16] levels; to decrease GB3 deposits in kidney endothe-
lial cells [15]; to slow the decline of the estimated glomerular filtration rate (eGFR) [15,16];
to reduce/stabilize left ventricular (LV) mass [14,18,19] and wall thickness [19]; to im-
prove/stabilize vestibular/auditory symptoms [20,21]; to improve nerve sensitivity [22],
gastrointestinal symptoms [23], sweat function [23], pain [15], and pain-related quality of
life [15].
In males, agalsidase beta has been shown to decrease plasma GB3 [24–27] and lyso-
GB3 [26] and urinary GB3 [25] levels; to decrease GB3 deposits in different kidney cell
types [24,25,28] and endothelial cells in skin [24,25]; to slow the decline of eGFR [25,29,30];
to reduce/stabilize LV mass [27,29,31,32] and wall thickness [27,32]; to improve nerve sen-
sitivity [33], gastrointestinal symptoms [34], sweat function [33,35], pain [35], and quality
of life [24,35].
In females, agalsidase alfa has been demonstrated to decrease plasma GB3 [36,37],
plasma lyso-GB3 [17,26] and urine GB3 [36,37] (when pre-treatment values were ele-
vated); to stabilize/decrease the decline of eGFR [19,36–38]; to decrease/stabilize LV
mass [18,19,36,37] and wall thickness [19]; to improve exercise capacity [37]; to stabilize
hearing loss and vestibular function [21]; and to improve quality of life [36].
In females, agalsidase beta has been shown to stabilize plasma GB3 (when pre-
treatment values were normal) [26]; to decrease plasma lyso-GB3 [26] (when pre-treatment
values were elevated); to stabilize eGFR [29]; to decrease/stabilize LV mass [29,32] and
wall thickness [32]; and to improve quality of life [39].
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Agalsidase alfa and beta are generally safe. The most common adverse events are
infusion associated reactions (IAR), which are mild or moderate and tolerable in most
cases [14,15,40,41] (Table 1).
Table 1. Currently approved therapies for adult patients with FD.
Agalsidase Alfa Agalsidase Beta Migalastat
Definition Recombinant α-galactosidase Aproduced from human fibroblasts [11]
Recombinant α-galactosidase A
produced from Chinese hamster ovary
(CHO) cells [11]
Low molecular weight iminosugar
analogue of the terminal galactose
residue of GB3 [42–44]
Mechanism of
action Enzyme replacement therapy [11] Enzyme replacement therapy [11]
Pharmacological chaperone that
selectively and reversibly binds to the
active site of amenable mutant forms
of α-galactosidase A, stabilizing it,
preventing its retention in the ER,
and enabling its trafficking to the
lysosomes [42–44]
Administration
route Intravenous [45] Intravenous [46] Oral [47]
Dose and frequency
of administration 0.2 mg/Kg every other week [45] 1 mg/Kg every other week [46] 123 mg once every other day [47]
Efficacy
Males
 Decreases plasma GB3 [14–16]
and lyso-GB3 [17] and urinary
GB3 [14,16] levels
 Decreases GB3 deposits in
kidney endothelial cells [15]
 Slows the decline of eGFR
[15,16]






 Improves nerve sensitivity [22],
gastrointestinal symptoms [23],
sweat function [23], pain [15]
and pain-related quality of
life [15]
Females
 Decreases plasma GB3 [36,37],
plasma lyso-GB3 [17,26],
and urine GB3 [36,37] (when
pre-treatment values were
elevated)
 Stabilizes/decreases the decline
of eGFR [19,36–38]
 Decreases/stabilizes LV mass
[18,19,36,37] and wall
thickness [19]
 Improves exercise capacity [37]
 Stabilizes hearing loss and
vestibular function [21]
 Improves quality of life [36]
Males
 Decreases plasma GB3 [24–27]
and lyso-GB3 [26] and urinary
GB3 [25] levels
 Decreases GB3 deposits in
different kidney cell types
[24,25,28] and endothelial cells
in skin [24,25]
 Slows the decline of eGFR
[25,29,30]
 Reduces/stabilizes LV mass
[27,29,31,32] and wall thickness
[27,32]
 Improves nerve sensitivity [33],
gastrointestinal symptoms [34],
sweat function [33,35], pain [35],
and quality of life [24,35]
Females
 Stabilizes plasma GB3 (when
pre-treatment values were
normal) [26]
 Decreases plasma lyso-GB3 [26]
(when pre-treatment values
were elevated)
 Stabilizes eGFR [29]
 Decreases/stabilizes LV mass
[29,32] and wall thickness [32]
 Improves quality of life [39]
 Decreases plasma lyso-GB3
[48,49]
 Decreases mean number of GB3
inclusions/kidney interstitial
capillary [48] and mean total
GB3 inclusion volume per
podocyte [50]
 Reduces mean LV mass index
[48,49,51–55]
 Improves diarrhoea [48,56]
 No change in eGFR, mGFR,
24 h-urine protein excretion and
24 h urinary GB3 in pivotal
clinical trials [48,51]; however,
decline of eGFR was reported in
some real-life studies [49,54]
Safety
 IAR are the most common side
effects (mainly mild, such as
fever and chills) [14,15]
 Hypersensitivity reactions are
rare [45]
 Anti-drug antibodies in 20% of
treated males [14]
 IAR are the most common side
effects (mainly mild, such as
fever and chills) [40,41]
 Hypersensitivity reactions are
rare [46]
 Anti-drug antibodies in 91% of
treated males [57]
 Headache and nasopharyngitis
are the most common side
effects [48,51]
 No immunogenicity issues [58]
eGFR, estimated glomerular filtration rate; ER, endoplasmic reticulum; IAR, infusion associated reactions; LV, left ventricular; mGFR,
measured glomerular filtration rate.
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2.2. Best Timing to Start ERT
According to the current recommendations, ERT should be initiated (i) in classic males
at the age of 16 years regardless of symptomatic status, although it should be considered
earlier, on an individual basis, since the age of 8–10 years old; and (ii) in late-onset males
and in classic/late-onset females with signs/symptoms of FD (LVH, cardiac fibrosis, cardiac
rhythm or conduction abnormality, microalbuminuria/proteinuria non-attributed to other
causes, chronic kidney disease (eGFR <90 mL/min/1.73 m2), stroke or transient ischemic
attack, neuropathic pain, gastrointestinal symptoms such as abdominal pain or diarrhoea,
anhidrosis/hypohidrosis). In asymptomatic late-onset males and classic/late-onset females,
ERT could be considered in the presence of moderate or severe GB3 deposits, podocyte
foot process effacement, or glomerulosclerosis on kidney biopsy [11].
Early treatment has clearly been shown to achieve better outcomes.
Classic males who started ERT before the age of 25 years achieved greater reduction
of plasma lyso-GB3 than the ones who started after that age [59]. Patients who started
agalsidase beta at the age <30 years experienced a statistically significant decline in LV
mass, while those who started it at the age ≥50 years suffered an increase in LV mass [31].
Likewise, patients who started agalsidase beta at the age <40 years had stable thickness of
the interventricular septum and posterior wall over a period of 10 years, whereas patients
who started it at the age ≥40 years significantly progressed over time [60]. Moreover,
in patients without fibrosis, agalsidase beta resulted in a statistically significant decline of
LV mass and improvement of exercise capacity and LV radial strain rate, while no effect
was observed in patients with mild or severe fibrosis at the time of treatment initiation [61].
Additionally, the slope of eGFR decline was lower in patients who started agalsidase
beta earlier since symptom onset and before the development of significant glomeruloscle-
rosis and proteinuria [30,60].
Finally, the risk of clinical events was lower in patients who started agalsidase beta
at younger age [62] and before severe organ damage [62,63]. Likewise, the risk of clinical
events seemed to be lower in classic males who started ERT before the age of 25 years
compared to the ones who started ERT later [59].
2.3. Optimal Dose of ERT
2.3.1. Agalsidase Alfa vs. Agalsidase Beta at Licensed Dose
In classic males, the reduction in plasma lyso-Gb3 was significantly larger in patients
treated for 1 year with agalsidase beta at the dose of 1.0 mg/kg than in patients treated
with agalsidase alfa or beta at the dose of 0.2 mg/kg [26].
In another study, the reduction of plasma lyso-GB3 in classic males treated for 1 year
with agalsidase beta 1 mg/Kg was greater than with agalsidase alfa 0.2 mg/Kg, and the
same was observed in females and non-classic males. Additionally, a higher proportion of
patients had a decrease in LV mass index when treated for 1 year with agalsidase beta than
with agasidase alfa (79% vs. 62%). Nevertheless, no difference between agalsidase alfa and
beta was found regarding eGFR or clinical events [64].
Another study showed that 19.4% of patients on agalsidase alfa 0.2 mg/Kg and 13.3%
of patients on agalsidase beta 1 mg/Kg progressed, during the 59-month study duration,
to a composite clinical endpoint consisting of renal events (development of end-stage renal
disease or sustained decline in GFR of 50% or greater for more than 30 days and for which
other causes besides FD had been excluded), cardiovascular events (pacemaker or other
intracardiac device, coronary artery bypass grafting, valve replacement surgery, coronary
angioplasty or stent, cardioversion, hospitalization or emergency room visit for unstable
angina/acute coronary syndrome, myocardial infarction, congestive heart failure, tachy-
or brady-arrhythmia, heart block, cardiac arrest), cerebrovascular events (TIA or stroke
documented by a physician or acute hearing loss), or death. However, these differences
were not significant due to limited power [65].
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2.3.2. Agalsidase Beta at Reduced Dose
The dose reduction of agalsidase beta from 1 mg/Kg eow to 0.3 mg/Kg eow for
18 months allowed for maintaining the clearance of GB3 deposits in the kidney interstitial
capillary endothelium in 90% of the patients; and the clearance/reduction of GB3 deposits
in other renal cells and superficial dermal capillary endothelium in only 70% of the patients.
Additionally, urinary GB3 increased significantly after dose reduction [25].
In another study, the dose reduction of agalsidase beta from 1 mg/Kg eow to 0.5 mg/Kg
per month for 1 year led to a significant increase of plasma lyso-GB3 in males, but no differ-
ences were seen on clinical events, Mainz Severity Score Index (MSSI), pain, eGFR, or LV
mass [66].
In the Fabry registry, the dose reduction of agalsidase beta resulted in lower self-
reported energy levels in males, but no difference in MSSI, DS3, Brief Pain Inventory (BPI),
or SF-36 scores [67].
2.3.3. Switch between Therapies
Patients under agalsidase beta 1 mg/kg eow, who switched directly to agalsidase alfa
0.2 mg/Kg eow or suffered a dose reduction to agalsidase beta 0.3–0.5 mg/kg eow and
then switched to agalsidase alfa 0.2 mg/Kg eow, showed a greater eGFR decline and an
increase of MSSI, GI symptoms [68,69], and pain [68], although clinical events remained
stable for 2 years [69].
In three young classic males under agalsidase beta 1 mg/kg eow for 5 years, there was
complete clearance of GB3 from mesangial and endothelial cells and partial clearance
from podocytes. Three years after the switch to agalsidase alfa 0.2 mg/Kg eow, there was
reaccumulation of GB3 in podocytes. One patient switched back to agalsidase beta 1 mg/Kg
eow and two years later again showed reduction of GB3 in podocytes. Additionally,
pain and GI symptoms worsened in all three patients following the switch from agalsidase
beta to alfa [70].
However, in another study, patients under agalsidase beta 1 mg/kg eow who switched
to agalsidase alfa 0.2 mg/Kg eow did not show any differences on plasma lyso-GB3 or
GB3, eGFR, proteinuria, or LV mass index for 2 years [17].
2.3.4. Agalsidase Alfa at Increased Dose
A study comparing patients under agalsidase alfa 0.2 mg/Kg eow and 0.2 mg/kg
weekly for one year did not find any significant differences in plasma GB3, LV mass, eGFR,
albuminuria, 6-min walk test, or quality of life. Exploratory analyses of patients under
0.4 mg/kg weekly did not find any differences either [71].
Additionally, a study comparing patients under agalsidase alfa 0.1 mg/kg weekly,
and 0.2 mg/Kg eow and 0.2 mg/Kg weekly for 4 weeks, did not find any significant
differences on plasma GB3, quality of life, or pain, although there was a trend for a higher
sweat volume and a lower urinary GB3 with the weekly dose of 0.2 mg/Kg [72].
Conversely, in patients with progressive decline of renal function despite agalsidase
alfa 0.2 mg/kg eow for 2–4 years, the switch to 0.2 mg/Kg weekly significantly decreased
the annual slope of eGFR during a 10 year-study, significantly delaying the time to end-
stage renal disease [73,74].
2.4. Limitations of ERT
ERT presents several potential limitations: (i) It has limited tissue penetration; (ii) it does
not pass the blood-brain barrier; (iii) it may induce infusion adverse reactions; (iv) it may
induce the production of anti-drug antibodies with neutralizing effect, reducing the effi-
cacy of the therapy; (v) it is a lifelong therapy requiring intravenous administration every
2 weeks; and (vi) it is associated to a high cost (Table 2).
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Table 2. Advantages and limitations of current therapies of FD.
Advantages Limitations
ERT
 Large body of evidence supporting its
efficacy and safety
 Long clinical experience,
being commercially available since 2001
 Incomplete reversion of FD pathology
and clinical manifestations
 Limited tissue penetration
 No crossing of the blood–brain barrier
 Infusion adverse reactions
 Anti-drug antibodies with neutralizing
effect may reduce the efficacy of ERT
 Lifelong therapy requiring intravenous




 Small molecule, likely to have enhanced
cellular and tissue distribution
 Sustained and stable enzyme levels
 Non-immunogenic molecule
 Favorable safety profile
 Therapeutic option only for patients with
amenable GLA mutations
 “In Vitro” amenability may not always
reflect “in vivo” amenability
 Not recommended in patients aged ≥75
or <16 years, pregnant or breastfeeding,
or with severe renal impairment (eGFR
<30 mL/min/1.73 m2) due to lack of data
 Incomplete reversion of FD pathology
and clinical manifestations
 High cost
eGFR, estimated glomerular filtration rate; ERT, enzyme replacement therapy; FD, Fabry disease.
2.4.1. Limited Tissue Penetration
The inefficient biodistribution of the exogenous recombinant enzyme may contribute
to the limited efficacy of ERT. While most of the administered recombinant enzyme is taken
up by the liver, cardiomyocytes and podocytes, despite being severely affected by FD,
only take up few amounts of recombinant enzyme, which might contribute to the limited
clearance of GB3 deposits in these cells [75,76].
Mannose 6-phosphate (M6P) mediated endocytosis has been considered the main
mechanism of uptake of recombinant α-galactosidase A. However, the rate of cellular up-
take among different tissues depends on the pattern of glycosylation and phosphorylation
of the enzyme, which is different between agalsidase alfa and agalsidase beta, because
post-translational protein modifications are specific to the species [77].
Nevertheless, blocking the M6P receptor inhibited the uptake of recombinant α-
galactosidase A in fibroblasts, but not in endothelial cells [78]. Moreover, in podocytes,
enzyme uptake is known to be mediated by M6P, megalin, and sortilin receptors, but block-
ing all three receptors only inhibited the uptake of recombinant enzyme by 39% [79].
These results suggest the existence of additional uptake mechanisms, which might explain
the existence of different biodistribution profiles among tissues.
2.4.2. No Crossing of the Blood-Brain Barrier
Stroke and TIA in Fabry patients have been attributed to cardioembolism or vas-
cular involvement by the disease; however, the pathophysiology of brain WML is prob-
ably more complex. GB3 deposits within the endothelial and smooth muscle cells of
the small and medium-size brain arteries may decrease vascular compliance and im-
pair autoregulation of cerebral perfusion and lead to endothelial dysfunction, increase of
pro-thrombotic/pro-inflammatory cytokines, and upregulation of the renin–angiotensin
system, which may result in ischemic events [80]. On the other hand, GB3 deposits were
also found in brain neurons and glia [81,82], although a clinical correlate remains to be
established [83]. Glial dysfunction and neuroinflammation may also contribute to the
development of brain WML [80]. Yet, their clinical impact is not fully understood.
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None of the recombinant enzyme preparations can pass the blood–brain barrier.
The effect of ERT on the development or progression of brain WML remains to be elucidated.
During a 2-year follow-up of six patients under agalsidase alfa, brain WML remained stable
in three patients, worsened in one, fluctuated in one, and improved in one patient; during
this time, some brain WML disappeared and others appeared on brain MRI [84]. During
a mean follow-up of 27 months, agalsidase beta seemed to stabilize brain WML on MRI
compared to placebo, as a statistically significant greater proportion of younger patients
(≤50 years) under agalsidase beta had stable WML compared with younger patients under
placebo (44% vs. 31%) [85].
2.4.3. Infusion-Associated Reactions
ERT leads to IAR, which occur mostly in the first 13 infusions and are mostly limited
to fever and chills [86], although life-threatening reactions have also been reported [87].
IAR occur in 14% of patients under agalsidase alfa [45] and 67% under agalsidase beta [46];
and the risk of IAR seems higher in males with nonsense or null mutations (CRIM nega-
tive) [86] and in patients with an anti-agalsidase IgG antibody–positive status [86,88].
2.4.4. Anti-Drug Antibodies
Anti-drug antibodies develop in the first 3–6 months of ERT [86,89], mostly in classic
males [90]. Anti-drug antibodies have been reported in 91% of males treated with agalsidase
beta [57] and 20% of males treated with agalsidase alfa [14], although no significant
difference in their formation has been reported when the same dosage (0.2 mg/kg every
2 weeks) was used for both drugs at ERT initiation [91]. Antibodies have shown in vitro
cross-reactivity to both agalsidase alfa and beta [89].
IgG antibodies measured by ELISA mediate a neutralizing activity [89]. Neutralizing
anti-drug antibodies develop in about 40% of all ERT-treated males [86,88] and mostly
in patients treated with agalsidase beta [64]. Their formation seems to be irreversible,
and the majority of patients positive for neutralizing anti-drug antibodies remain as so
over 10 years [64,88,91].
These anti-drug antibodies bind and neutralize ERT in plasma and lead to activation of
macrophages that internalize the ERT-antibody complexes, decreasing the cellular uptake
of ERT [89].
Neutralizing anti-drug antibodies may attenuate ERT efficacy. Anti-drug antibod-
ies have been associated to higher frequency of GB3 deposits in endothelial cells of the
skin [92] and higher plasma lyso-GB3 [64,88,91,93] and urinary GB3 [89,91]. Although
previous reports have suggested that anti-drug antibodies had no effect on the time to first
clinical event or eGFR slope [92], other studies have shown that they were associated to
worse renal function [88,93] and higher LV mass, disease severity scores, and frequency of
symptoms [88].
Increasing the ERT dose in patients with established anti-drug antibodies may saturate
them and allow for the excess enzyme to perform its catalytic function, thereby attenu-
ating the negative effect of anti-drug antibodies in plasma lyso-Gb3, eGFR, and LV wall
thickness [94].
3. Migalastat
3.1. Efficacy and Safety of Migalastat
Migalastat is a first-in-class pharmacological chaperone therapy for FD. It is a low
molecular weight iminosugar analogue of the terminal galactose residue of GB3 that selec-
tively and reversibly binds to the active site of amenable mutant forms of α-galactosidase
A, thereby stabilizing the enzyme, preventing its retention and degradation in the endoplas-
mic reticulum, and facilitating its trafficking to lysosomes. Once in lysosomes, migalastat
dissociates from α-galactosidase A, due to the more acidic pH and higher concentration of
substrates, allowing the enzyme to exert its activity on GB3 [42–44].
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Migalastat is an oral drug administered at the dosage of 123 mg once every other day,
which has been approved in 2016 by the European Medicines Agency for the treatment
of FD patients aged ≥16 years, with eGFR ≥30 mL/min/1.73 m2 and amenable GLA
mutations [47].
In the FACETS trial, in the modified-intention to treat population (i.e., ERT-naïve
patients with migalastat-amenable GLA mutations), migalastat, compared to placebo, sig-
nificantly reduced the plasma lyso-GB3 and the mean number of GB3 inclusions/kidney
interstitial capillary at 6 months. There were no significant differences in baseline lev-
els or changes from baseline to month 6 between the groups regarding eGFR, mGFR,
24 h-urine protein excretion, and 24 h urinary GB3. At 24 months of migalastat therapy
(i.e., after 18 months of migalastat in patients who switched from placebo or 24 months
of continuous migalastat), there was a significant reduction of the mean LV mass index
compared to the baseline [48]. An improvement in diarrhea was also found after 6 months
of migalastat compared to placebo, and this benefit was sustained at 24 months [48,56].
Those results were also confirmed in the subgroup of classic males [95]. Migalastat treat-
ment was also demonstrated to decrease the mean total GB3 inclusion volume per podocyte
in renal biopsies from baseline to 6 months; and this reduction correlated with the reduction
in mean podocyte volume [50].
In the ATTRACT trial, in ERT-experienced patients with amenable GLA mutations
who were randomized to switch to migalastat or continue ERT, renal function and plasma
lyso-GB3 levels were maintained during 18 months of migalastat or ERT. Migalastat sig-
nificantly reduced the mean LV mass index at 18 months, and changes on LV mass index
correlated with changes in the thickness of the interventricular septum and not the poste-
rior wall. No significant change of the mean LV mass index was found in the ERT group;
however, the randomization ratio of migalastat to ERT of 1.5 to 1, the existence of non-
amenable mutations in the initial cohort, and the higher discontinuation rate on the ERT
group resulted in a small number of evaluable patients under ERT at the end of the study
(16 patients), which may have influenced the results regarding ERT [51]. In the open-label
extension study, a significant decrease of LV mass index was found after 30 months of
migalastat in patients with LVH at baseline [52].
In real world conditions, Muntze et al. reported one patient with an improvement
of LV mass, LGE, troponin, and NT-proBNP after 12 months of treatment with migalas-
tat [53]. Later, the same authors showed that, in 14 patients treated with migalastat for
1 year, LV mass index significantly decreased, while plasma lyso-GB3 significantly de-
creased in naïve patients and remained stable in patients switched from ERT. However,
eGFR significantly worsened, a finding that contrasted to the results in the pivotal clinical
trials. The authors hypothesized that these results could have been partly explained by the
simultaneous initiation of angiotensin converting enzyme inhibitors and underlined the
need for further studies with longer follow-up of the renal function [49].
In a larger study including 59 patients, treatment of previously ERT-treated and
untreated FD patients with migalastat for 12 months was generally safe and also resulted in
a significant decrease of LV mass index. However, plasma lyso-GB3 levels were stable both
in males and females, irrespective of previous treatment regimen; and increasing plasma
lyso-GB3 was noted in a few males and females, some of whom carried GLA mutations
whose amenability to migalastat has been questioned. Moreover, eGFR continued to decline
under migalastat in both males and females. The loss of renal function did not seem to
be explained by a more severe renal impairment and disease load at baseline. Instead,
higher decline of eGFR was more common in patients with a systolic blood pressure below
120 mmHg. Additionally, females with GLA mutations, classified as non-amenable by the
in-house assay based on GLA-knockout HEK cells, had higher decline of eGFR. This study
recommended to avoid systolic blood pressure values below 120 mmHg and alerted
that “in vitro” amenability may not always reflect “in vivo” amenability to migalastat,
emphasizing the importance of monitoring clinical response to therapy [54].
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In a smaller study of seven FD males, who switched from ERT to migalastat, a signifi-
cant decrease of LV mass index was also observed after 1 year of treatment with migalastat,
while plasma lyso-GB3 remained stable. Unlike previous real-life studies, eGFR was sta-
ble and proteinuria significantly decreased [55]. Therefore, further studies are needed to
understand the discrepant results of migalastat on renal function.
Migalastat is generally well tolerated, with headache and nasopharyngitis being the
most common side effects [48,51]. Transient and fully reversible infertility was also found
in male rats, but its occurrence in humans remains to be established [47] (Table 1).
3.2. “In Vitro” and “In Vivo” Amenability to Migalastat
The amenability of GLA mutations to migalastat is determined by a good laboratory
practice (GLP) “in vitro” pharmacogenetics assay, which has been clinically validated.
This assay uses human embryonic kidney (HEK) 293 cells that have been transfected with
individual GLA-containing DNA plasmids to measure increases in α-galactosidase A ac-
tivity in response to migalastat. According to Benjamin et al., GLA mutations that do not
qualify for testing include large deletions, insertions, truncations, frameshift mutations,
and splicing mutations; these mutations are classified as non-amenable. GLA mutations
that qualify for testing include missense mutations, nonsense mutations near the car-
boxyl terminus, small insertions and deletions that maintain reading frame, and complex
mutations comprising two or more of these types of mutations on a single GLA allele.
Migalastat-amenable mutations are defined as GLA mutations that translate to mutant
forms of α-galactosidase A that, in the presence of 10 µmol/L migalastat, display an in-
crease of the enzymatic activity ≥1.2-fold over baseline and an absolute increase ≥3% of
the enzymatic activity quantified as a percentage of the enzymatic activity of the wild-type
α-galactosidase A [96]. It is estimated that 35–50% of FD patients have mutations that are
amenable to migalastat [51].
However, recent studies have reported that migalastat was associated to an insufficient
increase of the enzymatic activity of α-galactosidase A and increasing values of plasma
lyso-GB3 in patients with certain GLA gene mutations classified as amenable based on the
“in vitro” GLP-HEK assay, thereby raising concerns that “in vitro” amenability may not
always reflect “in vivo” amenability [54,97,98]. Hence, serial measurement of the enzymatic
activity of α-galactosidase A in leukocytes and monitoring of the clinical response are
mandatory in order to assess “in vivo” amenability to migalastat.
3.3. Limitations and Potential Advantages of Migalastat
Migalastat is a therapeutic option only for patients with amenable GLA
mutations [47,48,51,96]. Due to the lack of data, migalastat is not recommended in patients
aged ≥75 or <16 years, pregnant or breastfeeding, or with severe renal impairment (eGFR
<30 mL/min/1.73 m2) [47,48,51].
Migalastat presents several potential advantages: (i) It is an oral therapy, thereby
eliminating the requirement for lifelong intravenous infusions; (ii) it is a non-immunogenic
molecule, avoiding antibody-related tolerability issues of ERT; (iii) it allows for sustained
and stable enzyme levels that more closely mimic those of endogenous wild-type enzymes,
whereas ERT leads to fluctuating and intermittent enzymatic activity; (iv) as a small
molecule, it is likely to have enhanced cellular and tissue distribution; (v) and potential to
cross the blood-brain barrier [58], as suggested by the finding of increased α-galactosidase
A activity and reduced GB3 levels in the brain of Fabry transgenic mice [99] (Table 2).
3.4. Emerging New FD Therapies
Current therapies have not shown to be able to fully revert FD pathology and clinical
manifestations. Therefore, several new therapies are under research, including new forms
of ERT (pegunigalsidase alfa, moss-derived α-galactosidase A), substrate reduction therapy
(lucerastat, venglustat), mRNA therapy, and genetic therapy [12,13] (Table 3).
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Pegunigalsidase alfa, a chemically modified α-galactosidase A enzyme produced in a
tobacco plant cell based ProCellEX system, is constituted by two subunits of α-galactosidase
A covalently bound by a chain of polyethylene glycol (PEG), which increases its stability
and reduces its clearance, thereby extending its plasma half-life [100–102] and allowing
a monthly infusion [102]. Being plant-derived, this enzyme does not display M6P on
their surface glycans [100], which suggests an alternative mechanism of cell uptake and
may result in a different biodistribution profile from agalsidase alfa and agalsidase beta.
This enzyme has already been demonstrated (i) to decrease plasma lyso-Gb3 levels and per-
itubular capillary Gb3 deposits in the kidney; (ii) to improve the BPI score, gastrointestinal
symptoms, and MSSI; (iii) and to maintain eGFR, proteinuria and LV mass on MRI with no
“de novo” cardiac fibrosis [101]. Studies to further test its efficacy are ongoing [102,103].
Anti-drug antibodies occurred in 19% of cases and became negative after 1 year, suggest-
ing induction of immune tolerance [101], but its effect on the immune system is not yet
completely clear [13]. Immune tolerance may occur as a result of the extended half-life and
higher exposure of the immune system to the enzyme; or because pegylation may mask
the enzyme to the immune system. However, concerns about immunogenicity have also
been raised, because of the different glycosylation pattern of a plant-derived protein and
the PEG component. Of note, the extended half-life may also interfere with the laboratory
assays for anti-drug antibodies detection, as the circulating enzyme at the sampling time
may bind antibodies and prevent their detection [13].
Table 3. Potential advantages and limitations of emerging therapies of FD.
Potential Advantages Potential Limitations
Pegunigalsidase alfa  Higher plasma half-life [100–102], allowing a
monthly infusion [102]
 Anti-drug antibodies in 19% of cases [101]
 Plant-derived protein with a different glycosylation
pattern—possible immunogenicity issues? [100]
 Unclear effect on the immune system [13]
 No crossing of the blood–brain barrier [13]




 Higher cellular uptake via the mannose
receptors [104,105]
 Plant-derived protein with a different glycosylation
pattern—possible immunogenicity issues? [104]
 Unclear effect on the immune system [104]
 No crossing of the blood–brain barrier [13]




 Oral administration [13]
 Non-immunogenic [13]
 Possible crossing of the blood-brain barrier [106]
 Complete block of a single enzymatic reaction could
potentially disrupt the cell homeostasis [13]
 May not be sufficient as monotherapy for patients
with minimal/no residual enzymatic activity [13]
mRNA therapy
 Potential for a larger interval between
infusions [107,108]
 Uses endogenous protein translation system to
ensure proper folding, glycosylation,
and intracellular trafficking of α-galactosidase A [13]
 No risk of insertional mutagenesis [13]
 Primarily targets hepatocytes [13]
 Unclear effect on immune system in classic
males [13]
Gene therapy
 Introduces a correct version of the GLA gene [12]
 Uses endogenous protein translation system to
ensure proper folding, glycosylation,
and intracellular trafficking of α-galactosidase A [13]
 Targeting all affected cell types and tissues is a
challenge [13]
 Risk of insertional mutagenesis [13]
 Unclear effect on immune system in classic
males [13]
Moss-derived α-galactosidase A is produced in the moss Phycomitrella patens and is a
glycoengineered variant devoid of α-1,3-fucose and β-1,2-xylose residues on its N-glycans
that are plant-specific and may elicit immunogenic response in mammals [104]. Being plant-
derived, this enzyme does not display M6P on their surface glycans; instead, it carries
>90% mannose-terminated glycans [104]. This enzyme has a shorter half-life, which might
be due to a higher cellular uptake via the mannose receptors [104,105], and has shown to
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reduce urinary Gb3 in a higher proportion than previously reported for α-galactosidase A
produced in mammalian cells [105].
The glucosylceramide synthetase (GCS) inhibitors, such as venglustat and lucerastat,
block the enzyme catalyzing the first step of glycosphingolipid biosynthesis, reducing
glucosylceramide and Gb3 [13]. In patients with residual enzyme activity, GCS inhibitors
might be sufficient to reduce the synthesis of GB3 to a level manageable by the residual
enzyme activity, while in classic patients, with minimal to no residual enzyme activity,
they may not be sufficient in monotherapy, but can still be useful in combination with
ERT [13]. Venglustat, also known as ibiglustat, has shown to reduce GB3 deposits in
tissues (including in brain) and plasma GB3 and lyso-GB3 in mice, this effect being more
pronounced when added to ERT, except in the brain, where ERT had no effect [106]. Prelim-
inary data also showed the reduction of Gb3 from superficial skin capillary endothelium
and plasma lyso-Gb3 in treatment-naïve Fabry patients [13]. Lucerastat added to ERT
resulted in a reduction of plasma GB3, while no reduction was seen in patients under ERT
alone; and in stabilization of renal and cardiac parameters at 12 weeks [109]. Despite the
clear advantages of oral administration, absence of anti-drug antibodies, and the possibility
of passing the blood-brain barrier, caution in dosing should be taken, because the complete
block of a single enzymatic reaction could potentially disrupt the cell homeostasis [13].
mRNA therapy, encapsulated in lipid nanoparticles, primarily targets hepatocytes
in which the enzyme is produced and secreted into the circulation [13]. In mice and non-
human primates, mRNA therapy has been shown to reduce GB3 and lyso-GB3 in heart
and kidney [107,108] and plasma [108], and this effect was maintained for up to six weeks
after infusion, suggesting that it could have the advantage of a larger interval between
infusions [107,108]. Unlike ERT, mRNA therapy carries the advantage of using the endoge-
nous protein translation system to ensure proper folding, glycosylation, and intracellular
trafficking of α-galactosidase A; and, unlike DNA-based therapy, it does not carry a risk
for insertional mutagenesis [13].
Gene therapy, using viral or non-viral vectors, may introduce a correct version of
GLA gene, through “in vivo” or “ex vivo” technology [12]. The first FD patients have been
treated in phase I and II clinical trials using an “ex vivo” approach, in which hematopoietic
stem cells of the patient were recruited, transfected using lentiviruses, and re-administered
to the patient. The main challenge is to target all affected cell types and tissues. Addi-
tionally, it is unclear whether classic males will develop antibodies against the expressed
enzyme [13].
4. Conclusions
Despite ERT has demonstrated efficacy and safety on the treatment of FD, there are still
pending questions about the best regimen and timing to start therapy as well as limitations,
such as the limited tissue penetration, the immunogenicity issues, and the inconvenience
of lifelong biweekly intravenous administrations.
Migalastat, the first-in-class pharmacological chaperone therapy for FD, has proven
to be safe and efficacious in patients with amenable GLA mutations. Being an oral non-
immunogenic drug, migalastat has overcome some of the limitations of ERT; however,
clinical evidence is still growing, amenability issues have been reported, and its clinical use
is limited to about 35–50% of FD patients.
As both therapies have been unable to fully revert FD pathology and clinical mani-
festations, this remains an enthusiastic field of investigation, with several new emerging
therapies under research and development, such as new forms of ERT, substrate reduction
therapy, and mRNA and gene therapies. So far, it remains unclear if optimal treatment lies
on a single therapy or combination of therapies; and whether other therapeutic strategies,
beyond the correction of the enzymatic defect alone, will be needed to avoid or revert
organ damage in FD.
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